Dr. Stefan Riedl Selected as Prestigious “V Foundation Scholar”
LA JOLLA, Calif. , November 13, 2006
Stefan Riedl, Ph.D., assistant professor at the Burnham Institute for Medical Research has been named as one of 15 cancer researchers to receive the prestigious 2006 V Foundation Scholar Grant. As a V Foundation Scholar, Dr. Riedl will receive $100,000 over a two-year period to support his research project, "Exploring the structural mechanisms of cancer signaling complexes for drug development".
V Scholar Grants provide a springboard for cancer researchers at the beginning of their careers. Support for training young investigators is regarded as the cornerstone of The V Foundation for Cancer Research, founded jointly by ESPN and the late Jim Valvano, former North Carolina State basketball coach and sports commentator, to help find a cure for cancer.
"We are grateful to the V Foundation for its support of Dr. Riedl at this critical juncture as he establishes his independent laboratory," said Dr. Kristiina Vuori, director of the NCI-designated Cancer Center at Burnham. "Dr. Riedl exemplifies the spirit of the V Foundation’s vision in supporting cancer research that has great promise in translating basic scientific discoveries to prototype cancer treatments."
Dr. Riedl earned his Ph.D. in 2002 in the laboratory of Nobel laureate Dr. Robert Huber at the Max Planck Institute in Munich, Germany. He moved to Princeton University for postdoctoral training where he received the prestigious Leukemia & Lymphoma Society career development fellowship award. Dr. Riedl then worked with Dr. Robert Liddington at the Burnham briefly as a research fellow, prior to joining Burnham’s NCI-designated Cancer Center as assistant professor in the Apoptosis & Cell Death Research Program in February 2006.
In choosing to establish his laboratory at the Burnham, Dr. Riedl will join the Institute’s robust drug discovery effort that includes a Center of Excellence for cancer drug discovery, one of only eight funded by the National Cancer Institute in the nation, and the San Diego Center for Chemical Genomics at Burnham, established by the National Institutes of Health as one of 10 collaborating centers, known collectively as the "Molecular Libraries Screening Centers Network". The MLSCN network is a flagship program of the new NIH roadmap initiative, which represents the world’s largest independent drug discovery effort and operates an open source database that will expedite the sharing of new information about potential drug discovery leads for cancer and other diseases with medical researchers worldwide.